论文部分内容阅读
目的探讨T2DM口服降糖药(OADs)血糖控制不佳的患者应用格列美脲联合甘精胰岛素治疗的临床效果。方法将102例OADs血糖控制不佳的T2DM患者按随机数字表法分为观察组和对照组。观察组予格列美脲联合甘精胰岛素;对照组予格列美脲联合中效胰岛素(NPH)。治疗20周后,比较两组的疗效和安全性。目的治疗后,观察组FBG、2hBG、BMI、HbA1c较对照组下降(P<0.05);组内比较,除BMI外,FBG、2hBG、HbA1c差异均有统计学意义(P<0.05);观察组HDL-C升高幅度大于对照组,而TG、TC、LDL-C下降幅度大于对照组(P<0.05)。结论 OADs血糖控制不佳的患者甘精胰岛素联合格列美脲对比NPH联合格列美脲疗效前者更优。
Objective To investigate the clinical effects of glimepiride combined with insulin glargine in patients with poor glycemic control of T2DM oral hypoglycemic agents (OADs). Methods Totally 102 T2DM patients with poorly controlled blood glucose of OADs were divided into observation group and control group according to random number table method. The observation group was given glimepiride combined with insulin glargine; while the control group was given glimepiride combined with medium-acting insulin (NPH). After 20 weeks of treatment, the efficacy and safety of the two groups were compared. After treatment, the FBG, 2hBG, BMI and HbA1c in the observation group were significantly lower than those in the control group (P <0.05). In addition, the differences of FBG, 2hBG and HbA1c except the BMI were statistically significant (P <0.05) HDL-C increased more than the control group, while TG, TC, LDL-C decreased more than the control group (P <0.05). CONCLUSIONS: Glargine and glimepiride are superior to NPH and glimepiride in patients with poorly controlled blood glucose control on OADs.